INCY financials show only 28 million in shareholder equity
and their only revenues are from JAKAFI yet they command
a $7.5B market cap. GERN at 7.5B market cap would be
Gern won't get there until Imetelstat goes onto market, however,
unless it is bought out first. Maybe INCY will merge with them.
I have read that JAKAFI and Imetelstat could be complimentary
treatment to occur concurrently, that they are not necessarily
competitors in the true sense of the word, but could be dosed
in conjunction. 1 for 1 share swap with Incy ?
Sentiment: Strong Buy
I don't believe Incyte has deep enough pockets, but Geron is too small by far to go it alone. Suggested from time to time have been: Merck, JNJ, Gilead, Celgene. We may hear more after ASH on Tuesday.
Yeah, yeah, and just "maybe" the "fringe lunatics on this forum" will, one day, stop pulling smelly, feces-festered, conjectures.....such as yours.....from the dank, dark, depths of their odoriferous, cheese-impacted, but totally clueless colons.